Biosimilars – up or down?
In this issue:
EU pushes the uptake of biosimilars
Faced with an uncertain regulatory background and the prospect of trials nearly as demanding as those faced by new clinical substances, many of the segment's once enthusiastic pharma proponents have backed out of programmes or put projects on hold. At the BIO congress in Chicago in late April, the European Commission presented its latest study on the sector - which makes a case that the positive aspects of biosimilars for both manufacturers and patients still far outweigh potential downsides.